Sanofi responds to the suspension of lipid-lowering drugs in China: Due to global supply issues, as well as the company's cardiovascular market strategy and pipeline optimization.

On August 4th, a notice letter called "Notice Regarding Praluent" circulated in the market, involving Sanofi's PCSK9 inhibitor class lipid-lowering drug alirocumab. The letter indicated that Sanofi will stop promoting the drug in China, leading to a shortage of supply in the country. In response, Sanofi China told a reporter from The Paper that the decision to stop supply is mainly due to global supply issues, as well as the company's cardiovascular market strategy and pipeline optimization. The company acquired the exclusive development and commercialization rights of aficamten in the Greater China region from Ji Xing by the end of 2024, and recently announced the acquisition of the rights for the investigational drug Pralsetinib sodium injection in the Greater China region from Viatris. The company's cardiovascular product strategy in China will undergo a comprehensive upgrade, continuing to provide innovative products in different fields to meet the needs of domestic patients.